GO
Loading...

Enter multiple symbols separated by commas

Life Sciences

More

  • *Initial Phase I clinical study starts in Britain. *First tests in Britain, more planned in U.S. and Africa. LONDON, Jan 6- Johnson& Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing.

  • *Initial Phase I clinical study starts at Oxford University. *Further tests planned for United States and Africa. LONDON, Jan 6- Johnson& Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing.

  • Dec 23- The U.S. Department of Health and Human Services awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines. Under a $30 million contract, NewLink's unit BioProtection Systems Corp will conduct clinical trials to determine the lowest dose at which its vaccine...

  • Dec 19- Shares of cancer drug developer Juno Therapeutics Inc soared as much as 65 percent in their market debut on Friday, capping a big year for biotech IPOs. Shares were priced at $24 per share, above the expected $21- $23. As of Sept. 30, Seattle- based Juno had raised about $314 million in private venture funding from investors including Amazon.com Inc co-founder...

  • Dec 19- Shares of Juno Therapeutics Inc, a biopharmaceutical company working on cancer treatments, rose as much as 64.5 percent in their market debut, valuing the company at about $3 billion. The stock touched a high of $39.50 shortly after trading started on the Nasdaq on Friday. The offering was priced at $24 per share, above the raised range of $21- $23.

  • GENEVA, Dec 19- Trials of GlaxoSmithKline's experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information. Countries where the trials are planned-- Cameroon, Ghana, Mali, Nigeria and Senegal-- should receive and review the additional...

  • *Shares in GSK partner Agenus jump 10 percent. LONDON, Dec 18- An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group's expanding vaccine unit a potential $1 billion boost. The data suggests the British company's new shot could be a strong competitor for Merck& Co's established vaccine...

  • LONDON, Dec 18- An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business. The adjuvant includes a component from U.S. biotech firm Agenus, which is entitled to royalties on any future sales. Merck& Co already sells another...

  • LONDON/ GENEVA, Dec 11- GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines, as one experimental shot hit a snag in a Swiss clinical trial after some subjects reported joint pains. GAVI, which is funded by governments and the Bill& Melinda Gates Foundation, said it was ready to begin procurement as soon as the...

  • LONDON, Dec 11- GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines and was ready to begin procurement as soon as the World Health Organization recommends one for use. Clinical trials with experimental shots are now underway as experts race to contain an epidemic that has killed more than 6,000 people in...

  • LONDON, Dec 11- GAVI, the global vaccines alliance, has committed up to $300 million to buy Ebola vaccines and is ready to begin procurement as soon as the World Health Organisation recommends one for use, the alliance said on Thursday. Up to an additional $90 million could also be used to support countries to introduce the vaccines and to rebuild their health...

  • Arca's potential Ebola drug gets "orphan drug status" Wednesday, 10 Dec 2014 | 11:19 AM ET

    Dec 10- Arca Biopharma Inc said the U.S. Food and Drug Administration granted its experimental drug orphan drug status as a potential treatment for viral hemorrhagic fever after exposure to the Ebola virus. The Westminster, Colorado- based company, whose stock rose about 11 percent on Wednesday, joins a list of drugmakers looking for ways to fight the largest...

  • This data represents a "quantum leap" in the management of this disorder by shifting from "life-long symptom management to once-and-done cures," Roth Capital Partner's Debjit Chattopadhyay said, raising his price target on the stock to $90 from $50. LentiGlobin's results read-through favorably to the sickle-cell indication, Piper Jaffray analysts said,...

  • CHICAGO, Dec 9- The U.S. Department of Health and Human Services on Tuesday offered liability protections to drugmakers rushing to develop Ebola vaccines and urged other countries to follow suit. Health and Human Services Secretary Sylvia Burwell made the announcement as part of the Public Readiness and Emergency Preparedness Act in a move aimed at...

  • LONDON, Dec 8- Pfizer Inc is moving into the gene therapy space in the latest sign that the technology for fixing faulty genes may finally be ready for prime time, following earlier setbacks. The Spark program is expected to enter early-stage clinical trials for hemophilia B in the first half of 2015. Spark will be responsible for the early Phase I/II tests, with...

  • Record iPhone 6 sales would have been even better Monday, 22 Sep 2014 | 11:04 AM ET
    iPhone 6 Plus

    In Monday's The Good, The Bad, and The Ugly: iPhone 6 sales top record; a poll shows attitudes towards corporations; and a German firm shops in U.S.

  • German firm buys American, but not for taxes: CEOs Monday, 22 Sep 2014 | 8:09 AM ET
    The Merck KGaA logo sits outside the company's headquarters in Darmstadt, Germany.

    Merck agrees to acquire Sigma-Aldrich for $17 billion in cash to boost its life science business.

  • Medical marijuana research hits wall of US law Sunday, 10 Aug 2014 | 7:54 AM ET
    A man purchases medical marijuana, the first legal sale, at Capital City Care in Washington, DC. The District of Columbia city council is to vote on decriminalizing pot.

    U.S. scientists face legal obstacles and frustrations in trying to study the medical uses of marijuana, the New York Times reports.

  • AstraZeneca Chair: Shareholders, 'vote me away' Monday, 19 May 2014 | 11:14 AM ET

    As AstraZeneca's shares slid following its rejection of Pfizer's new bid, the company's chairman said he was "reasonably confident" it was the right decision.

  • Euro strength still hurting business: DSM CFO Friday, 9 May 2014 | 3:47 AM ET

    The escalating euro continues to harm business, the chief financial officer of Royal DSM told CNBC, a day after the single currency took a beating.